Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index

Abstract

BackgroundThe only available predictive models for the outcome of breast cancer patients in New Zealand (NZ) are based on data in other countries. We aimed to develop and validate a predictive model using NZ data for this population, and compare its performance to a widely used overseas model, the Nottingham Prognostic Index (NPI).MethodsWe developed a model to predict 10-year breast cancer-specific survival, using data collected prospectively in the largest population-based regional breast cancer registry in NZ (Auckland, 9182 patients), and assessed its performance in this data set (internal validation) and in an independent NZ population-based series of 2625 patients in Waikato (external validation). The data included all women with primary invasive breast cancer diagnosed from 1 June 2000 to 30 June 2014, with follow up to death or Dec 31, 2014. We used multivariate Cox proportional hazards regression to assess predictors and to calculate predicted 10-year breast cancer mortality, and therefore survival, probability for each patient. We assessed observed survival by the Kaplan Meier method. We assessed discrimination by the C statistic, and calibration by comparing predicted and observed survival rates for patients in 10 groups ordered by predicted 10-year survival. We compared this NZ model with the Nottingham Prognostic Index (NPI) in this validation data set.ResultsDiscrimination was good: C statistics were 0.84 for internal validity and 0.83 for an independent external validity. For calibration, for both internal and external validity the predicted 10-year survival probabilities in all groups of patients, ordered by predicted survival, were within the 95% confidence intervals (CI) of the observed Kaplan-Meier survival probabilities. The NZ model showed good discrimination even within the prognostic groups defined by the NPI.ConclusionsThese results for the New Zealand model show good internal and external validity, transportability, and potential clinical value of the model, and its clear superiority over the NPI. Further research is needed to assess other potential predictors, to assess the model’s performance in specific subgroups of patients, and to compare it to other models, which have been developed in other countries and have not yet been tested in NZ.Electronic supplementary materialThe online version of this article (10.1186/s12885-018-4791-x) contains supplementary material, which is available to authorized users.

Construction of a Five-Super-Enhancer-Associated-Genes Prognostic Model for Osteosarcoma Patients

“…We adapted WGCNA to identify the five screened genes from SE-associated genes that were crucial hub genes of osteosarcoma. Prognostic models based on some cancer-related genes (Long et al, 2018;Zuo et al, 2019), long non-coding RNAs (Liu et al, 2020;Yang et al, 2020;, or other biomarkers (Park et al, 2017;Elwood et al, 2018) for improving patient prognosis attract considerable attention. For instance, Zhu et al (2020) constructed a seven-gene signature associated with osteosarcoma energy metabolism for predicting the prognosis of osteosarcoma through WGCNA and Lasso Cox regression analysis.…”

An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data

“…There has been a growing inclination in recent literature toward the use of FDG-PET/CT as a non-invasive hybrid imaging tool for forecasting treatment response in women with newly diagnosed breast cancer, especially in the context of neoadjuvant systemic therapy [21][22][23][24][25][26][27][28][29][30][31][32][33][34]. A vast majority of the existing models for treatment response prediction in breast cancer have traditionally leaned toward linear statistical methodologies, notably the Cox proportional hazards analysis.…”

“…Recent investigations have spotlighted the utility of baseline FDG-PET/CT for predicting outcomes in melanoma and non-small-cell lung cancer (NSCLC) patients [18][19][20]. In the context of breast cancer, there has also been a rising interest in recent literature in using FDG-PET/CT as hybrid imaging to predict response to treatment, particularly in the context of neoadjuvant systemic therapy [21][22][23][24][25][26][27][28][29][30][31][32][33][34]. Despite a significant heterogeneity of variables defined as outcomes, most of the published models predicting treatment response in breast cancer have predominantly relied on linear statistical approaches, such as Cox proportional hazards analysis.…”

Development and validation of a web‐based calculator to predict individualized conditional risk of site‐specific recurrence in nasopharyngeal carcinoma: Analysis of 10,058 endemic cases

“…Second, we did not include the effect of treatment in our model. Previous studies have suggested that treatment (e.g., radiotherapy alone versus chemoradiotherapy) should not be included in prediction models as a covariate unless the treatment data are derived from randomized clinical trials; otherwise, it may introduce bias (e.g., multicollinearity), as treatments are highly dependent on patient clinical characteristics in real-world clinical practice [17,[48][49][50][51][52]. Given this information, we excluded treatment in our models.…”